Dermtech Inc (DMTK)
$0.644
+0.05
(+8.97%)▲
Insights on Dermtech Inc
Increasing Revenue
Revenue is up for the last 2 quarters, 3.91M → 3.92M (in $), with an average increase of 0.2% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -31.36M → -19.09M (in $), with an average increase of 32.0% per quarter
Vs IQV
In the last 1 year, Iqvia Holdings Inc. has given 12.5% return, outperforming this stock by 99.1%
Vs TMO
In the last 3 years, Thermo Fisher Scientific, Inc. has given 5.1% return, outperforming this stock by 103.5%
Performance
- $0.60$0.69$0.64
6.25%
Downside
Day's Volatility :12.89%
Upside
7.08%
- $0.59$4.36$0.64
7.81%
Downside
52 Weeks Volatility :86.47%
Upside
85.32%
Returns
| Period | Dermtech Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -53.1% | -0.7% | 0.0% |
6 Months | -53.83% | 7.7% | 0.0% |
1 Year | -86.63% | 3.3% | -1.7% |
3 Years | -98.42% | 13.9% | -20.7% |
Highlights
Market Capitalization | 20.5M |
Book Value | $1.66 |
Earnings Per Share (EPS) | -3.09 |
Wall Street Target Price | 2.75 |
Profit Margin | 0.0% |
Operating Margin TTM | -503.36% |
Return On Assets TTM | -37.82% |
Return On Equity TTM | -106.46% |
Revenue TTM | 15.3M |
Revenue Per Share TTM | 0.47 |
Quarterly Revenue Growth YOY | 31.1% |
Gross Profit TTM | 647.0K |
EBITDA | -96.2M |
Diluted Eps TTM | -3.09 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.03 |
EPS Estimate Next Year | -1.75 |
EPS Estimate Current Quarter | -0.56 |
EPS Estimate Next Quarter | -0.57 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 327.02%
Technicals Summary
Sell
Neutral
Buy
Dermtech Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Dermtech Inc | -13.99% | -53.83% | -86.63% | -98.42% | -94.04% |
 Idexx Laboratories, Inc. | -10.6% | 12.24% | -2.03% | -9.61% | 115.62% |
 Agilent Technologies Inc. | -10.14% | 20.94% | -4.67% | -0.79% | 75.25% |
 Thermo Fisher Scientific, Inc. | -7.07% | 15.3% | -6.62% | 11.05% | 109.01% |
 Danaher Corp. | -6.85% | 14.02% | -7.22% | -2.33% | 86.3% |
 Iqvia Holdings Inc. | -10.62% | 21.64% | 12.54% | 5.06% | 69.06% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Dermtech Inc | NA | NA | NA | -2.03 | -1.06 | -0.38 | NA | 1.66 |
Idexx Laboratories, Inc. | 47.4 | 47.4 | 4.75 | 11.13 | 0.81 | 0.23 | NA | 17.88 |
Agilent Technologies Inc. | 31.68 | 31.68 | 2.7 | 5.5 | 0.21 | 0.08 | 0.01 | 21.12 |
Thermo Fisher Scientific, Inc. | 35.85 | 35.85 | 2.81 | 21.56 | 0.13 | 0.05 | 0.0 | 120.87 |
Danaher Corp. | 42.54 | 42.54 | 3.13 | 7.62 | 0.08 | 0.04 | 0.0 | 72.36 |
Iqvia Holdings Inc. | 31.16 | 31.16 | 1.33 | 11.11 | 0.23 | 0.05 | NA | 33.67 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Dermtech Inc | Buy | $20.5M | -94.04% | NA | 0.0% |
Idexx Laboratories, Inc. | Buy | $39.7B | 115.62% | 47.4 | 23.08% |
Agilent Technologies Inc. | Buy | $38.8B | 75.25% | 31.68 | 18.35% |
Thermo Fisher Scientific, Inc. | Buy | $211.7B | 109.01% | 35.85 | 13.99% |
Danaher Corp. | Buy | $178.0B | 86.3% | 42.54 | 19.94% |
Iqvia Holdings Inc. | Buy | $41.3B | 69.06% | 31.16 | 9.06% |
Institutional Holdings
Vanguard Group Inc
4.07%BlackRock Inc
1.26%Hongkou Capital LP
1.16%Morgan Stanley - Brokerage Accounts
1.13%Geode Capital Management, LLC
0.87%White Pine Capital LLC
0.56%
Corporate Announcements
Dermtech Inc Earnings
Dermtech Inc’s price-to-earnings ratio stands at None
Read More
Company Information
dermtech is a molecular diagnostic dermatology company focused on developing non-invasive gene expression tests to aid the clinical diagnosis of skin cancer and other skin conditions. dermtech operates a clia (clinical laboratory improvement amendments) licensed laboratory located at the company’s la jolla, ca headquarters. dermtech’s technology allows for the analysis of skin biopsy samples collected non-invasively using an adhesive patch. current dermatologic diagnosis is primarily based on subjective visual pattern recognition that is prone to error and results in a substantial number of unnecessary surgical procedures. dermtech’s pigmented lesion assay (pla) provides physicians with a non-invasive option for the biopsy of clinically atypical pigmented lesions using an adhesive patch rather than a scalpel. dermtech provides highly accurate, objective information to the physician to improve patient care and comfort and reduce costs. the pla is used for the detection of melanoma in at
Organization | Dermtech Inc |
Employees | 206 |
CEO | Mr. Kevin Sun M.B.A. |
Industry | Finance |
